FCCC LOGO Faculty Publications
Ozols RF
Chemotherapy for ovarian cancer
Semin Oncol. 1999 Dec;26(6 Suppl 18) :34-40
Back to previous list
Abstract
Prospective randomized trials have established carboplatin plus paclitaxel as the preferred combination chemotherapy for patients with advanced ovarian cancer. However, clinical issues remain to be determined regarding the use of this regimen. These include the optimization of dose and schedule, the role of maintenance therapy, any potential role of high-dose chemotherapy with hematologic support, and the role of intraperitoneal chemotherapy. In addition, new drug combinations that add new agents (eg, topotecan, gemcitabine, or etoposide) to the standard two-drug combination of paclitaxel plus carboplatin need to be evaluated.
Notes
0093-7754 Journal Article Review Review, Tutorial